Follicum expands its collaboration with two prominent hair clinics for the implementation of the next Phase IIa study with FOL-005
Follicum AB ("Follicum") recently made a preferential share issue which provided the company with SEK 23.5 million before costs. The liquidity paid to the company is partly intended to finance a Phase IIa clinical trial with the company's drug candidate FOL-005. Follicum hereby announces that the company has chosen to work with the Clinical Research Center for Hair and Skin ("CRC") in Berlin and Bioskin in Hamburg for the implementation of the forthcoming study. Follicum intends to submit a clinical study application to the German Medicines Agency, BfArM, shortly, with the ambition to